Targeting HIV reservoirs in the brain and lymphoid tissues for long-term remission
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV
This study is testing a new treatment that uses specially modified immune cells to target and get rid of hidden HIV in the brain and lymph nodes, aiming to help people with HIV stay healthy without needing to take daily medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11130928 on NIH RePORTER |
What this research studies
This research focuses on developing a new immunotherapy that uses genetically modified T cells to target and eliminate HIV reservoirs in the central nervous system and lymphoid tissues. By understanding how HIV persists in these areas, particularly in myeloid cells, the researchers aim to create a treatment that can provide long-lasting remission from HIV without the need for ongoing antiretroviral therapy. The approach involves using CAR T-cell therapy, which is designed to specifically attack HIV-infected cells, potentially leading to a functional cure for people living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not achieved viral suppression or are experiencing viral rebound after stopping antiretroviral therapy.
Not a fit: Patients who are newly diagnosed with HIV or those who are not yet on antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a one-time treatment that allows individuals with HIV to achieve long-term remission without continuous medication.
How similar studies have performed: While targeting HIV reservoirs is a novel approach, there have been preliminary successes in using CAR T-cell therapy for other conditions, indicating potential for similar advancements in HIV treatment.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Skinner, Pamela J — University of Minnesota
- Study coordinator: Skinner, Pamela J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.